◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

CapForce IBD Breakout Opportunities ETF (BOUT) ETF Overview

Name: CapForce IBD Breakout Opportunities ETF (BOUT) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Mid-Cap Growth · DATA UPDATED 2026-08-31

CapForce IBD Breakout Opportunities ETF (BOUT) is an exchange-traded fund managed by Capital-FORCE ETF in the "Mid-Cap Growth" category. It manages roughly $16 million in assets.

The fund normally invests at least 80% of its net assets (including borrowings for investment purposes) in the equity securities that comprise the index.

Interactive chart & fund stats →

BOUT Fund Statistics

Expense ratio	0.80%
Trailing yield	0.27%
Assets under management	$16 million
Fund category	Mid-Cap Growth
Fund family	Capital-FORCE ETF
Inception	2018-09-12

The live price chart, fund profile and news are in the interactive BOUT viewer.

Other Companies in Mid-Cap Growth

TMFX · Motley Fool Next Index ETF — $33 million
BCSM · Baron SMID Cap ETF — $32 million
JMID · Janus Henderson Mid Cap Growth Alpha ETF — $24 million
PJFM · PGIM Jennison Focused Mid-Cap ETF — $19 million
TEKX · State Street Galaxy Transformative Tech Accelerators ETF — $16 million
SSMG · Virtus Silvant Small/Mid Growth ETF — $3 million
PCSG · Polen 5Perspectives Small-Mid Growth ETF — $3 million
QMID · Wisdomtree U.S. Midcap Quality Growth Fund — $2 million

← BOTZ All “B” companies BOW →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.